Navigation Links
Medical Breakthrough ... Doctor Discovers 'Penetrating Carrier' That Eradicates Fungus
Date:11/7/2007

Innovative Custom Products, Inc., has obtained exclusive distribution rights to a 'first of its kind' product line, CureCeuticals, invented by Dr. Marc Selner, a nationally renowned Sports Podiatrist; Cure Toenail

Fungus and Cure Athlete's Foot.

MILWAUKEE, Nov. 7 /PRNewswire/ -- Joe Williams, President and Founder of Innovative Custom Products, Inc., announced today that his firm obtained exclusive distribution rights to a "first of its kind" product line, CureCeuticals, invented by Dr. Marc Selner, a nationally renowned Sports Podiatrist. The lead products in the CureCeuticals line are Cure Toenail Fungus and Cure Athlete's Foot. Both products are all-natural, all-organic, allopathic and homeopathic formulations. These cutting edge products are available without prescription and come in a convenient travel size. Williams said a full Skin Care line utilizing Dr. Selner's breakthrough "penetrating carrier technology" is in development and will be ready for distribution under the CureCeuticals brand within the next 12-18 months.

According to Dr. Selner, Cure Toenail Fungus is the only patent pending OTC topical that actually penetrates the nail, kills the fungus, and allows growth of a new, healthy nail. Cure Athlete's Foot unique formulation allows it to work on contact and eliminates most Athlete's Foot, Jock Itch, and Ringworm within 48 hours. Cure Athlete's Foot also relieves the itching, burning, and scaling associated with these conditions immediately upon application. These products have been used for years in doctors' offices to successfully treat and remedy toenail fungus (Onychomycosis) and athlete's foot (Tenia Pedis), respectively, without side effects.

Dr. Selner said that, unlike other products, Cure Toenail Fungus and Cure Athlete's Foot utilize his "Penetrating Carrier Technology" to allow the contained anti-fungal compounds to actually penetrate the nail or the skin and go directly to where the fungus resides and other topicals do not reach. This delivery system is a major breakthrough; no other OTC product even claim to penetrate the nail and reach the nail bed. The only competitive product is a prescription drug that requires doctor visits and blood tests every six weeks because of its known side effects, and could cost as much as $1,400 for comparable results.

Innovative Custom Products, Inc., a Wisconsin corporation in business since 1992, is a manufacturer and distributor of consumer and pharmaceutical products. According to Williams, consumers are driving the demand for organic products and big box retailers are now paying attention. Williams believes the CureCeuticals product line will generate over $20 million in sales within the next couple years. These products are currently sold in independent pharmacies throughout the USA and are expected in national drug chains soon. Negotiations are currently in place to open the European markets and Williams hopes to open the Canadian and Caribbean markets in 2008. To contact Investor Relations or Distribution Services, email us at: contact@icpCorporation.com or telephone us at (414) 358-1802.

To contact Investor Relations or Distribution Services, email us at: contact@icpCorporation.com or telephone us at (414) 358-1802.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.


'/>"/>
SOURCE Innovative Custom Products, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Ecovia Renewables, Inc. announced ... (SBIR) grant from the National Science Foundation (NSF). Under the award , ... suite of BioGelâ„¢ biopolymer materials for hygiene applications, particularly for use in the ...
(Date:3/28/2017)... Belgium , March 28, 2017 Volition America, ... VNRX), today announced the engagement of Deborah Vollmer Dahlke ... a strategic consultant. Dr. Vollmer Dahlke,s role will ... funding in the State of Texas ... Dr. Vollmer Dahlke has significant experience over the ...
(Date:3/28/2017)... March 28, 2017 Biostage, Inc. ... developing bioengineered organ implants to treat cancers and other ... announced that Jim McGorry, CEO of Biostage, ... panel at the MassBio 2017 Annual Meeting ... ET in Cambrige, Massachussetts. The 3D Printing and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... MultiMountTM weigh modules. These weigh modules are designed according to European Hygienic ... (NSF). , As fully integrated weighing solutions, SWB805 MultiMount weigh modules reduce ...
Breaking Biology Technology:
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud ... Continue Reading ... Used combined in one project, multi-biometric solutions provide a ... Used combined ... ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):